Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening

MYC family members are among the most frequently deregulated oncogenes in human cancers, yet direct therapeutic targeting of MYC in cancer has been challenging thus far. Synthetic lethality provides an opportunity for therapeutic intervention of MYC-driven cancers.